Page 359 - Haematologica Vol. 109 - July 2024
P. 359
CASE REPORT AB
C
D
E
Figure 1. Clinical course and antiviral antibody titers of a myeloma patient #1 with COVID-19-related acute respiratory distress syndrome. (A) Computed tomographic (CT) images of chest for Patient 1. Axial and coronal sections display diffuse and extensive alveolar damage showing ground-glass consolidations that persist after 1 week of intensive care unit (ICU) treatment including high-dose steroids and remdesivir. (B) Supplemental O2 requirement of our patient while admitted to the ICU. Both fraction of inspired oxygen (FIO2) (red) and O2 flow rates (orange) are indicated. Dosing of defibrotide (blue) and intravenous immunoglobu- lin (IVIG) (green) are indicated by vertical dashed lines. Administration of both tocilizumab (toci; black dot) and dexamethasone (dex; black line) for cytokine release syndrome (CRS) are indicated as is administration of remdesvir (yellow line). (C) Reciprocal immungolbulin (Ig)G antibody endpoint titers against SARS-CoV-2 proteins spike (S)1 (red), S2 (orange), and nucleocapsid protein
Haematologica | 109 July 2024
2373
Continued on following page.
